Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-4547. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 12/20 | 0.75 |
| ▸ | FGFR2 known ✓ | P21802 | 3/20 | 0.47 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | MARK3 | P27448 | 1/20 | 0.75 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.75 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.75 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.75 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.75 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.75 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.75 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.75 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.75 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.75 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.75 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexagratinib SCHEMBL63884 | 1.00 | FGFR1 (0.75) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Azd-4547 SCHEMBL19338066 | 1.00 | FGFR1 (0.75) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL19338029 | 0.95 | FGFR1 (0.68) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL65023 | 0.90 | FGFR1 (0.61) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL15241153 | 0.90 | FGFR1 (0.61) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL1921969 | 0.87 | FGFR1 (0.57) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL64476 | 0.87 | FGFR1 (0.57) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL1921961 | 0.87 | FGFR1 (0.57) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Azd-4547 SCHEMBL22132858 | 0.86 | FGFR1 (1.00) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Azd-4547 SCHEMBL15433983 | 0.86 | FGFR1 (1.00) | FGFR1NTRK1RETPDGFRBMARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226960-B2 | FGF modulation of in vivo antibody production and humoral immunity | BUSH ANDREW B (US) | 2016-01-05 | — | — | US | claimed |
| WO-2014155268-A2 | FGF-R TYROSINE KINASE ACTIVITY INHIBITORS - USE IN DISEASES ASSOCIATED WITH LACK OF OR REDUCED SNF5 ACTIVITY | NOVARTIS AG (CH) | 2014-10-02 | — | — | WO | claimed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | claimed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | claimed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | claimed |
| US-20240309463-A1 | USE OF FGFR MUTANT GENE PANELS IN IDENTIFYING CANCER PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH AN FGFR INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-19 | — | — | US | disclosed |
| WO-2024031226-A1 | PHARMACEUTICAL COMPOSITION AND POLYMORPHIC SUBSTANCE OF FGFR INHIBITOR, AND PHARMACEUTICAL USE THEREOF | 无锡和誉生物医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
| CN-117320724-A | FGFR tyrosine kinase inhibitor for treating advanced solid tumor | 詹森药业有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116669763-A | FGFR inhibitor combination therapy | 詹森药业有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-115103678-A | FGFR tyrosine kinase inhibitors for the treatment of high risk non-muscle invasive bladder cancer | 詹森药业有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115087446-A | FGFR tyrosine kinase inhibitor and anti-PD 1 agent for treating urothelial cancer | 詹森药业有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-113957146-A | Identification of cancer patients who will respond to treatment with FGFR inhibitors using FGFR mutant genomes | 詹森药业有限公司 | 2022-01-21 | — | — | CN | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FGFR1 823/4885FGFR2 939/4885FGFR3 1462/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FGFR1 168/4885FGFR2 603/4885FGFR3 773/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | FGFR1 823/4885FGFR2 939/4885FGFR3 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.